Literature DB >> 24532398

Unstable oxygen supply and glaucoma.

K Konieczka1, S Fränkl2, M G Todorova1, P B Henrich1.   

Abstract

The pathogenesis of the glaucomatous optic neuropathy (GON) is an ongoing bone of contention. While the role of intraocular pressure (IOP) is well known, it is also clear that a variety of other factors, particularly those of a vascular nature, are involved as well. In contrast to other eye diseases, it is an unstable oxygen supply, as opposed to chronic hypoxia, that contributes to GON. The major cause of fluctuations in the local oxygen tension is an unstable ocular blood flow (OBF). OBF, in turn, fluctuates if the IOP spikes, blood pressure drops, or OBF autoregulation is defective. The main reason for disturbed autoregulation is a primary vascular dysregulation (PVD), particularly in the context of the so-called Flammer syndrome. Unstable oxygen tension leads to local oxidative stress with many detrimental effects, such as the activation of glial cells, which alters their morphology and gene expression. As a consequence, the local concentrations of nitric oxide and the metalloproteinases increase. The metalloproteinases digest extracellular matrix and thereby contribute to tissue remodelling. The short-lived nitric oxide easily diffuses into the neighbouring neuronal axons, allowing a fusion with the superoxide anion and thereby generating the cell-damaging peroxynitrite. Both this tissue remodelling and damage of the axons contribute to the development and progression of GON. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24532398     DOI: 10.1055/s-0033-1360242

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  11 in total

Review 1.  Metalloproteinases as mediators of inflammation and the eyes: molecular genetic underpinnings governing ocular pathophysiology.

Authors:  Mahavir Singh; Suresh C Tyagi
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

2.  Laser cyclophotocoagulation enhances the regulative capacity of retinal vessels in glaucoma.

Authors:  Stephan Kremmer; Gerasimos Anastassiou; Maurice Schallenberg; Klaus-Peter Steuhl; Vilser W; Michael Selbach J
Journal:  Open Ophthalmol J       Date:  2014-06-13

3.  The effect of flammer-syndrome on retinal venous pressure.

Authors:  Lei Fang; Michael Baertschi; Maneli Mozaffarieh
Journal:  BMC Ophthalmol       Date:  2014-10-13       Impact factor: 2.209

4.  Multiple sclerosis and primary vascular dysregulation (Flammer syndrome).

Authors:  Katarzyna Konieczka; Simone Koch; Tatjana Binggeli; Andreas Schoetzau; Juerg Kesselring
Journal:  EPMA J       Date:  2016-06-15       Impact factor: 6.543

Review 5.  Diseases potentially related to Flammer syndrome.

Authors:  Katarzyna Konieczka; Carl Erb
Journal:  EPMA J       Date:  2017-09-13       Impact factor: 6.543

Review 6.  Flammer syndrome.

Authors:  Katarzyna Konieczka; Robert Ritch; Carlo Enrico Traverso; Dong Myung Kim; Michael Scott Kook; Augusto Gallino; Olga Golubnitschaja; Carl Erb; Herbert A Reitsamer; Teruyo Kida; Natalia Kurysheva; Ke Yao
Journal:  EPMA J       Date:  2014-07-08       Impact factor: 6.543

Review 7.  Ocular Blood Flow and Normal Tension Glaucoma.

Authors:  Ning Fan; Pei Wang; Li Tang; Xuyang Liu
Journal:  Biomed Res Int       Date:  2015-10-19       Impact factor: 3.411

Review 8.  Systemic and Ocular Hemodynamic Risk Factors in Glaucoma.

Authors:  Jaewan Choi; Michael S Kook
Journal:  Biomed Res Int       Date:  2015-10-18       Impact factor: 3.411

Review 9.  The discovery of the Flammer syndrome: a historical and personal perspective.

Authors:  Josef Flammer; Katarzyna Konieczka
Journal:  EPMA J       Date:  2017-05-22       Impact factor: 6.543

10.  Choroidal infarction in a glaucoma patient with Flammer syndrome: a case report with a long term follow-up.

Authors:  Barbara Terelak-Borys; Iwona Grabska-Liberek; Anita Piekarniak-Wozniak; Katarzyna Konieczka
Journal:  BMC Ophthalmol       Date:  2017-03-14       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.